Navigation Links
Refractory Hematological Malignancies (MDS, AML) Market Emerging Therapeutics Analysis Available at

Dallas, Texas (PRWEB) September 01, 2013

The report provides an overview of the approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in the race to launch new therapies for this indication – Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene are available as a separate or with the full report. Key M&A activities that have taken place in this area in the last five years and a list of products in early /late stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.

Get a copy of the complete report with comprehensive Table of Contents @

Reasons to buy the report :
Useful for investors, Scientists, Business development managers of Pharma companies with a focus in oncology to address the following-

  •     What are the opportunities or new approaches to be deployed in the R&D of the company?
  •     List of validated and new targets
  •     In-licensing opportunities – Is the way to go forward and be in the race?
  •     Commercial opportunity and companies’ valuation.

Key Points Discussed in the Report –
1.    Overview of the disease and Unmet need
2.    Drugs in the pipeline – Mechanism of Action (MoA) and Clinical Stage of development
a.    Myelodysplastic Syndromes – Lower-risk, Higher-risk, and recurrent / refractory MDS
b.    Acute Myeloid Leukemia – Untreated/ newly diagnosed and relapsed / refractory AML
3.    Key milestones
4.    Launch Timeline and Commercial Opportunity of Late-stage pipeline (RR MDS and RR AML)
5.    M&A and Licensing deals in the last 5 years
6.    In-licensing and/or M&A Opportunity
7.    Detailed Company analysis includes Clinical data of drugs , Milestones and Valuation for Ambit Biosciences (AMBI), Onconova Therapeutics (ONTX), Celgene (CELG) and SymBio (4582).

Place a direct purchase order @
Alternatively inquire for discount @

Explore above and other reports by MP Advisors @

About Us: is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers. Our database includes reports by leading publishers from across the globe. We also offer custom research services in case your requirements are not covered in the available syndicated market research reports in our database.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
2. Effects of alcohol on lymphoma, leukemia, and other types of hematological cancers
3. N-Butanol Market (Butyl Acrylate, Butyl Acetate, Glycol Ethers) worth $9.4 Billion by 2018 - New Report by MarketsandMarkets
4. Global Proteomics Market (Instrumentation Technology, Reagents & Services) Worth $17.2 Billion by 2017 - New Report by MarketsandMarkets
5. The Global Ophthalmology Devices and Drugs Market is Expected to Reach $52.6 Billion by 2017 - New Report by MarketsandMarkets
6. Contrast Media / Contrast Agents Market (Interventional Radiology & Interventional Cardiology) worth $8.6 Billion by 2017 - New Report by MarketsandMarkets
7. Transformer Oil Market (Mineral Oil - Naphthenic & Paraffinic) Worth $2.46 Billion by 2017 - New Report by MarketsandMarkets
8. Therapeutic Partnering Market Trends with 2013 Analysis in New Research Report at
9. Telerad Tech's RADSpa™ Announces Its Entry Into Brazil Markets
10. Flight Management Systems Market (Flight Management Computer, Flight Management Control Unit) Worth $1.8 Billion By 2018 – New Report by MarketsandMarkets
11. Slimming Kou Tea: The Newest Weight Loss Tea Released in the Market With 1 Month Extra Supply
Post Your Comments:
(Date:10/13/2015)... ... , ... Curly Hair Solutions® is thrilled to be a ... featuring the newest products and services to hit the market for women. With ... to unveil their recent partnership with Trade Secrets, a leading Canadian beauty retailer. ...
(Date:10/12/2015)... TN (PRWEB) , ... October 13, 2015 , ... ... recipients of its biannual Heroes in Recovery Awards at Foundations Recovery Network’s Moments ... Recovery Network presented the one-of-a-kind awards to Noah Levine and Dean Dauphinais who ...
(Date:10/12/2015)... ... 12, 2015 , ... According to an article from ... particularly in the area of track and field, are at a significantly higher ... peers in the same age group. Dr. Steven Meier of Meier Orthopedic Sports ...
(Date:10/12/2015)... ... October 12, 2015 , ... American Family Care (AFC), the nation’s ... by opening its 151st medical center. Located at 606A Boll Weevil Circle in Enterprise, ... continue fulfilling our mission of making quality health care accessible and economical with the ...
(Date:10/12/2015)... ROSA, CA (PRWEB) , ... October 12, 2015 , ... ... (DSM) at no charge to qualified Managed Care Organizations (MCOs) in order to ... insight and analysis into their decision making process. In addition, the DSM is also ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... COSTA MESA, Calif. , Oct. 12, 2015 ... reaffirmed the accreditation of Harbor Compounding Pharmacy in ... accreditation is awarded in recognition of the pharmacy,s ... --> ... --> ...
(Date:10/12/2015)... Calif. , Oct. 12, 2015 /PRNewswire/ ... and Chief Scientific Officer of Asterias Biotherapeutics, ... company in the emerging field of regenerative ... webcast, sponsored in part by Asterias Biotherapeutics, ... Lebkowski will discuss the progress to date ...
(Date:10/12/2015)... , Oct. 12, 2015  In a Sutter ... the Journal of Neurology, Neurosurgery, and Psychiatry, the blood ... brain atrophy and cognitive decline in patients in the ... --> --> IVIG, extracted from the ... to amyloid, an abnormal brain protein found in patients ...
Breaking Medicine Technology: